GLPG2938 is a potent and selective S1P2 antagonist. GLPG2938 can be used for the research of idiopathic pulmonary fibrosis In Vitro GLPG2938 (0.5~5 μM; HPF cells) significantly prevents the S1P-mediated contraction at all tested concentrations. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo GLPG2938 (1~10 mg/kg; p.o.) displays a marked protective effect at all dosed tested, resulting in statistically significant reduction of the Ashcroft score . GLPG2938 shows good pharmacokinetics, with long half-life, low clearance, and good bioavailability in all species, especially in dogs . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL/6 mice Dosage: 1~10 mg/kg Administration: P.o. Result: Displayed a marked protective effect at all dosed tested, resulting in statistically significant reduction of the Ashcroft score. Form:Solid IC50& Target:S1PR2